Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients
Maria Grazia Bernengo(University of Milan), M. T. Fierro(University of Turin), M. Ortoncelli(University of Turin), Alessandra Comessatti(University of Turin), F Lisa(University of Turin), Pietro Quaglino(Department of Medical Sciences), Mauro Novelli(University of Turin)
Cited by 175
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas
|Journal of the American Academy of Dermatology|2002|493
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452